Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-14
2010-11-16
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S131000
Reexamination Certificate
active
07834039
ABSTRACT:
Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.
REFERENCES:
patent: 4003909 (1977-01-01), Narayanan et al.
patent: 6211234 (2001-04-01), Astles et al.
patent: 6277872 (2001-08-01), Brenner et al.
patent: 6579880 (2003-06-01), Weidner-Wells et al.
patent: 6992096 (2006-01-01), Karp et al.
patent: 7220745 (2007-05-01), Singh et al.
patent: 2001/0049367 (2001-12-01), Bennani et al.
patent: 2004/0024024 (2004-02-01), Freskos et al.
patent: 2005/0124675 (2005-06-01), Hsieh et al.
patent: 2006/0122397 (2006-06-01), Arora et al.
patent: 2006/0148863 (2006-07-01), Karp et al.
patent: 2008/0113961 (2008-05-01), Nishi et al.
patent: 2008/0200535 (2008-08-01), Ohmori et al.
patent: 2008/0269236 (2008-10-01), Ji et al.
patent: 962684 (1975-02-01), None
patent: 0504574 (1992-09-01), None
patent: 1845097 (2007-10-01), None
patent: WO 00/25768 (2000-05-01), None
patent: WO 01/19822 (2001-03-01), None
patent: WO 01/54507 (2001-08-01), None
patent: WO 01/66534 (2001-09-01), None
patent: 02/068417 (2002-09-01), None
patent: WO 02/092588 (2002-11-01), None
patent: 03/053986 (2003-07-01), None
patent: 03/059871 (2003-07-01), None
patent: 03/087044 (2003-10-01), None
patent: 03/087045 (2003-10-01), None
patent: 03/105771 (2003-12-01), None
patent: WO 03/105771 (2003-12-01), None
patent: 2004/035538 (2004-04-01), None
patent: WO 2004/035538 (2004-04-01), None
patent: 2004/048319 (2004-06-01), None
patent: 2005/032465 (2005-04-01), None
patent: 2005/058848 (2005-06-01), None
patent: WO 2005/048953 (2005-06-01), None
patent: 2005/070925 (2005-08-01), None
patent: 2005/082898 (2005-09-01), None
patent: WO 2005/051932 (2005-09-01), None
patent: WO 2006/008260 (2006-01-01), None
patent: WO2006/016724 (2006-02-01), None
patent: 2006/047195 (2006-05-01), None
patent: 2006/066126 (2006-06-01), None
patent: 2006/131336 (2006-12-01), None
patent: WO 2007/003960 (2007-01-01), None
patent: 2007/013830 (2007-02-01), None
patent: 2007/043400 (2007-04-01), None
patent: WO 2007/039781 (2007-04-01), None
patent: WO 2007/076055 (2007-07-01), None
patent: WO2007/080542 (2007-07-01), None
patent: 2007/085451 (2007-08-01), None
patent: 2007/098474 (2007-08-01), None
patent: WO 2007/098474 (2007-08-01), None
patent: 2007/132307 (2007-11-01), None
patent: WO2008/016692 (2008-02-01), None
patent: 2008/029370 (2008-03-01), None
patent: 2008/029371 (2008-03-01), None
patent: 2008/035239 (2008-03-01), None
patent: 2008/037476 (2008-04-01), None
patent: 2008/073942 (2008-06-01), None
patent: 2008/094053 (2008-08-01), None
patent: WO2008/114157 (2008-09-01), None
patent: 2008/131148 (2008-10-01), None
patent: 2008/151184 (2008-12-01), None
Vippagunta et al., Crystalline solids, 2001, Advanced Drug Delivery Reviews, 48, pp. 3 and 18.
Wolff et al., Burger's Medicinal Chemistry and Drug Discovery, 1994, Wiley-Interscience, Fifth Edition, vol. I: Principles and Practice, pp. 975-977.
Kwon et al., Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists, 2001, http://www.myilibrary.com/Browse/open.asp?ID=4284&loc=1, Retrieved from the Internet Jun. 16, 2008, p. 213.
Metabolomics [online], Retrieved from the Internet Jun. 16, 2008, URL: http://www.en.wikipedia.org/wiki/Metabolomics, p. 1.
Barrett, et al. “Chromatography-Free Synthesis of 1,2,4-Oxadiazoles Using ROMPGEL-Supported Acylating Reagents”, (2000), Combinatorial Chemistry & High Throughput Screening. (3): 131-138.
Deegan, et al. “Parallel Synthesis of 1,2,4-Oxadiazoles Using CDI Activation”, (1999), Bioorganic & Medicinal Chemistry Letters. (9): 209-212.
Antunes, et al. “Synthesis, characterization and interaction mechanism of new oxadiazolo-phthalimides as peripheral analgesics. IV”, (2003), Journal of Molecular Structure. (660): 1-13.
Antunes, et al. “New Phthalimide Derivatives with Potent Analgesic Activity: II”, (1998), Bioorganic & Medicinal Chemistry Letters. (8): 3071-3076.
Arakawa, et al. “Morphological and Enzymatic Alterations in the Rat Liver caused by Administration of a Hypocholesterolemic Agent at-308 and its Related Compounds”, (1978), Biochemical Pharmacology. (27): 167-171.
Nakai, et al. “Metabolic Disposition of 3-[4-(1-Ethoxycarbony 1-1 methylethoxy)pheny1]-5(3 pyridy)-1,2,4-oxadiazole (AT-308), a Hypocholesterolemic Agent, in Rats)”, (1977), J. Takeda Res. Lab. 36(½): 46-52.
Asahi, et al. “Properties and Stabilities of 3-[4-(1-Ethoxycarbony-1-Methylethoxy)phenyl]-5-(3-pyridy1)-1,2,4-oxadiazole (AT-308)”, (1976), J. Takeda Res. Lab. 35(¾): 151-158.
Yurugi, et al. “Studies on the Syntheses of N-Heterocyclic Compounds. IV.1)Hypocholesterolemic 1,2,4-Oxadiazole Derivatives. (2)”, (1973), Chem. Pharm. Bull. 21(9): 1885-1893.
Yurugi, et al. “Studies on the Synthesis of N-Heterocyclic Compounds. III.1) Hypocholesterolemic 1,2,4-Oxadiazole Derivatives (1)”, (1973), Chem. Parm. Bull. 21(8): 1641-1650.
Imai, et al. “Biological Studies of AT-308, Part 1 Hypocholesterolemic Effect of 1,2,4-Oxadiazole Derivatives in Rats”, (1973), Atherosclerosis. (17): 121-129.
Krippner, et al. “Synthesis and Antiviral Activity of Dimeric Capsid-Binding Inhibitors of Human Rhinovirus (HRV)”, (2004), Aust. J. Chem. (57): 553-564.
Neidlein et al. “Syntheses of 1,2,4-Oxadiazole substituted Pyrazole, Isoxazole and Pyrimidine Heterocycles”, (1996), J. Heterocyclic Chem. (33): 1943.
Bailey, et al “Acetylfurans as bio-isosteres for 3-methylisoxazole. The effect of acetylfuran positional isomers on antirhinoviral activity”, (1996), Antiviral Chemistry & Chemotherapy. 7(1): 46-52.
Giranda, et al. “Structures of Four Methyltetrazole-Containing Antiviral Compounds in Human Rhinovirus Serotpe 14”, (1995), Acta Cryst. (D51): 496-503.
Diana, et al. “Picomavirus Inhibitors: Triflouromethyl Substitution Provides a Globall Protective Effect against Hepatic Metabolism”, (1995), J. Med. Chem. (38) 1355-1371.
Bailey, et al. “An Evaluation of the Antirhinoviral Activity of Acylfuran Replacements for 3-Methylisoxazoles. Are 2-Acetylfurans Bioisosteres for 3-Methylisoxazoles?”, (1994), J. Med. Chem. (37) 4177-4184.
Bailey, et al. “Additions and Corrections—1994, vol. 37”, (1995), J. Med. Chem. (38):1416.
Yan, et al. “Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes”, (2006), Bioorganic & Medicinal Chemistry Letter. (16) 3679-3683.
Li, et al. “Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 S1P1) Receptor Agonists with Exceptional Selectivity against S1P2, and S1P3”, (2005), Journal of Medicinal Chemistry. 48(5): 6179-6173.
Torgova, et al. “Influence of Chemical Structure on the Mesomorphic Behaviour of 3,5-Disubstituted 1,2,4-Oxadiazoles”, (2002), Brazilian Journal of Physics. 32(2B): 593-601.
Karamysheva, et al. “Dependence of Mesomorphic Properties of 3,5-Disubstituted 1,2,4-Oxadiazoles on Geometric and Electronic Factors”, (1995), Mol. Cryst. Liq. Cryst. (260): 217-225.
Karamysheva, et al. “3,5-Disubstituded 1,2,4-Oxadiazoles—New Class of Liquid Crystalline Compounds”, (1994), Mol. Mat. (4): 289-293.
Guy D. Diana, et al., “Picornavirus Inhibitors: Trifluoromethyl Substitution Provides a Global Protective Effect against Hepatic Metabolism”, J. Med. Chem., 1995 vol. 38:1355-1371.
Ansell Graham K.
Breinlinger Eric C.
Cusack Kevin P.
Fix-Stenzel Shannon R.
Grongsaard Pintipa
Abbott Laboratories
Bianchi Kristin
Lwicker Kenneth P.
O'Brien Gayle B.
Saeed Kamal A
LandOfFree
Oxadiazole compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxadiazole compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxadiazole compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4205354